Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Assess the Safety and Antiviral Activity of PEG-rIL-29 Administered as a Single Agent and in Combination With Ribavirin in Treatment-Relapsed and Treatment-Naive Subjects With Chronic Hepatitis C Virus Infection

Trial Profile

A Phase 1 Study to Assess the Safety and Antiviral Activity of PEG-rIL-29 Administered as a Single Agent and in Combination With Ribavirin in Treatment-Relapsed and Treatment-Naive Subjects With Chronic Hepatitis C Virus Infection

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2009

At a glance

  • Drugs Peginterferon lambda-1a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors ZymoGenetics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Oct 2009 Results will be presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), held in Boston, Massachusetts from 30 Oct 2009 to 3 Nov 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top